ASCO 2014 – Colorectal and Head & Neck Cancer

Chemotherapy Plus Bevacizumab or Cetuximab in mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer

Racial Differences in KRAS/BRAF Mutation Rates and Survival in mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer

Early Predictors of Overall Survival in mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer

The Current Status of Biomarkers in Use for the Treatment of Patients with mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer

Updated Results of the SOFT Study

ASCO 2014 – Colorectal and Head & Neck Cancer

mCRC Daily News from ASCO 2014: May 30, 2014 - Preview of Key Topics

ASCO 2014 – Colorectal and Head & Neck Cancer

Impact of p16 Status on Cetuximab + Radiotherapy in Locally Advanced SCCHN

ASCO 2014 – Colorectal and Head & Neck Cancer

This was a retrospective analysis of the phase 3 IMCL-9815 trial assessing the role of HPV-p16 status in patients with locally advanced SCCHN receiving radiation therapy (RT) plus cetuximab (cetux) or RT alone (Rosenthal DI, et al. ASCO 2014. Abstract 6001). Read More ›

BRAF + MEK Inhibitors in mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer

BRAF Inhibitor + Cetuximab in mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer

Second-Line Therapies in KRAS–Wild-Type mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer

Page 2 of 3

1
2
3